For investors
Publications
Below is a selection of available results:
“Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone”
Bengt Glimelius, et al
Cancer Treatment Review, Volume 98, July 2021 >>
“MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer”
David A. Drubin, et al.
“Tumoral expression of folate-associated genes is associated with progression-free survival of patients with advanced colorectal cancer”
Yvonne Wettergren, et al.
“Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”
Roger Tell, et al.
“Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”
Helena Taflin, et al.
Springer Link, October, 2020 >>
“An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”
Heinz-Josef Lenz, et al.
“Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”
Stintzing, Sebastian, et al.
“ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”
Carlsson, Göran, et al.
“Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”
Gustavsson, Bengt, et al.
“A review of the evolution of systemic chemotherapy in the management of colorectal cancer”
Gustavsson, Bengt, et al.
Clinical colorectal cancer 14.1 (2015): 1-10 >>
“Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”
Danenberg, Peter V., et al.
Critial Reviews in Oncology/Hematology 106 (2016): 118-131 >>
“Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages”
Taflin, Helena, et al.
Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>
Last updated 07-06-2022
